Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2206 - Prognosis after loco-regional recurrence of breast cancer: 35 years longitudinal data from the Stockholm cancer register.


11 Sep 2017


Poster display session


Breast Cancer


Claudette Falato


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


C. Falato1, L. Eriksson1, A. Sofiadis1, S.K. Taylor2, A. Nordblom1, I. Fredriksson3, J. Hartman1, J. Bergh1, T. Foukakis1

Author affiliations

  • 1 Oncology And Pathology, Karolinska University Hospital-Solna, 17176 - Stockholm/SE
  • 2 Dep Of Medical Oncology, BC Cancer Agency, Kelowna BC/CA
  • 3 Molecular Medicine And Surgery, Karolinska University Hospital-Solna, 17176 - Stockholm/SE


Abstract 2206


Loco-regional recurrence (LRR) of breast cancer is a significant cause of morbidity and mortality. It is poorly described how prognosis after LRR has evolved over time at the population level.


2272 patients diagnosed with LRR between 1980-2014 were identified within the Stockholm cancer registry and divided in 7 cohorts by the year of LRR diagnosis. Post-relapse event free survival (EFS) and overall survival (OS) were analyzed separately in local and loco-regional relapses and compared across the cohorts by Cox regression method. Primary tumor size, axillary node status, estrogen receptor (ER) status, type of surgery, adjuvant chemotherapy, LRR free survival, and age at LRR were the covariates for Cox model adjustment.


In 1615 patients diagnosed with local relapse, 903 post-LRR events were registered (Table). A significant improvement in median EFS (p < .001) and OS (p < .001) was observed in patients diagnosed 2010-14 compared with previous time periods. Among 657 patients with loco-regional recurrences, 476 experienced a post-LRR event (Table). EFS and OS independently improved over time (p


Survival after LRR has gradually improved over the last 35 years regardless of other recognized prognostic factors.

Clinical trial identification

Legal entity responsible for the study

Karolinska Institutet


Dagmar Ferbsminnesfond


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.